<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Fingolimod" /><meta name="IX" content="Fingolimod" /><title>Fingolimod: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5700-fingolimod.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5700-fingolimod.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5700-fingolimod.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="PHP5665-other-immunomodulating-drugs.htm">8.2.4 Other immunomodulating drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5698-canakinumab.htm" title="Previous: CANAKINUMAB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5701-fingolimod.htm" title="Next: FINGOLIMOD">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a311004.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fingolimod Hydrochloride</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Biologic Response Modifiers 92:20</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22037-g.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Fingolimod</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: F &gt; Interactions of Fingolimod</p></div></li></ul><ul><li><h3>British National Formulary</h3></li><li><a href="PHP5701-fingolimod.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">FINGOLIMOD</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Fingolimod</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-22037-g.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fingolimod</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/04083.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fingolimod</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; F &gt; FI</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-F25.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fingolimod</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; F</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E4E3E0R0D1402.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Fingolimod</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; F</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><?highlighter on?><h1>Fingolimod</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Fingolimod</strong> is an immunomodulating drug licensed for use in patients with highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta or in those with rapidly evolving severe relapsing-remitting multiple sclerosis. Treatment with fingolimod should be initiated and supervised by a specialist.</p><div id="PHP18410" class="cI"><p class="cAE">MHRA/CHM advice</p> <h3 class="cT">Fingolimod: not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose (May 2012)</h3><p>Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before intiation:</p><p><strong>Patients with the following medical conditions</strong><strong>:</strong></p><ul><li><p>2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block</p></li><li>  <p>significant QT prolongation (QT-interval greater than 470 milliseconds in women, or greater than 450 milliseconds in men)</p> </li><li>  <p>history of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.</p></li></ul><p><strong>Patients receiving the following antiarrhythmic or heart-rate lowering drugs</strong><strong>:</strong></p><ul><li><p>class Ia or class III antiarrhythmics</p></li><li>  <p>beta blockers</p> </li><li>  <p>heart rate-lowering calcium channel blockers</p></li><li>  <p>other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).</p></li></ul><p>Monitoring of <strong>all</strong> patients receiving fingolimod should include the following at initiation and following interruption of treatment for more than 2 weeks:</p><p><strong>Pre-treatment</strong></p><ul><li><p>a 12-lead ECG and blood pressure measurement before starting</p></li></ul><p><strong>During the first 6 hours of treatment</strong></p><ul><li><p>continuous ECG monitoring for 6 hours</p></li><li>  <p>blood pressure and heart rate measurement every hour</p></li></ul><p><strong>After 6 hours of treatment</strong></p><ul><li><p>a further 12-lead ECG and blood pressure measurement</p> </li></ul><p>If heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.</p><p>In patients with evidence of clinically important cardiac effects during the first 6 hours of treatment, monitoring should be extended, including at least overnight, until resolution.</p> </div><p>The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a>has advised (August 2012) that fingolimod (<em>Gilenya</em>®) is accepted for restricted use within NHS Scotland as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta, with an unchanged or increased relapse rate or ongoing severe relapses, as compared to the previous year.</p><div id="PHP19152" class="cI"><p class="cAE">NICE guidance</p> <h3 class="cT">Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012)</h3><p>Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if:</p><ul><li><p>they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, <strong>and</strong></p></li><li>  <p>the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme.</p></li></ul><p>Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p> <p><a href="http://www.nice.org.uk/TA254">www.nice.org.uk/TA254</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5701-fingolimod"><a href="PHP5701-fingolimod.htm" title="FINGOLIMOD">FINGOLIMOD</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5698-canakinumab.htm">Previous: CANAKINUMAB</a> | <a class="top" href="PHP5700-fingolimod.htm#">Top</a> | <a accesskey="]" href="PHP5701-fingolimod.htm">Next: FINGOLIMOD</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>